Specific features of urinary system diseases in children with connective tissue dysplasia
Abstract
Urinary system diseases in children with differentiated connective tissue dysplasia have not been adequately investigated and the available information is extremely scarce. The diseases represent mainly minimal change disease as orthostatic proteinuria, microscopic hematuria, metabolic disturbances, structural (nephroptosis) and vascular abnormalities (aneurysms). Undifferentiated connective tissue dysplasia is an abnormality that is being actively explored by Russian investigators. Multiple organ dysfunctions attract the attention of physicians in many specialties, including nephrologists. Urinary system diseases as recurrent urinary tract infections, renal and calicopeMc malformations, bladder diseases, and severe congenital anomalies of the kidney and urinary tract (CAKUT) are often accompanied by the manifestations of connective tissue dysplasia. A number of authors have identified connective tissue disease markers (matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, transforming growth factor-p etc.) to evaluate sclerotic processes in the kidneys. There are single studies of these markers in Alport syndrome or au-tosomal dominant polycystic kidney disease while such data on the differentiated types of dysplasia (Ehlers-Danlos syndrome, Marfan's syndrome) are unavailable.
About the Author
T. A. Kryganova
Acad. Yu.E. Veltishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Комитет экспертов педиатрической группы «Дисплазия соединительной ткани» при Российском научном обществе терапевтов. Наследственные и многофакторные нарушения соединительной ткани. Алгоритмы диагностики, тактика ведения. Проект Российских рекомендаций. Педиатрия 2014; 93:5: 40. (The Committee of Experts pediatric group «Connective tissue dysplasia» with the Russian Society of Physicians. Hereditary and multifactorial disorders of connective tissue. Algorithms for diagnostic tactics. Russian project recommendations. Pediatriya2014; 93:5: 40.)
2. Jarvelainen H., Sainio A., Koulu M. et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 2: 198-223.
3. MandalA. Collagen Types and Linked Disorders. 2013; http:// www.news-medical.net/health/Collagen-Types-and-Linked-Disorders-(Russian) .aspx
4. Genovese F, Manresa Alba A., Leeming D. et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 2014; 7:4: doi:10.1186/1755-1536-7-4.
5. Miner J.H., Baigent C, Flinter F. et al. The 2014 International Workshop on Alport Syndrome. Kidney Int 2014; 86: 4: 679— 684.
6. Chen Y.M. Glomerular basement membrane and related glo-merular disease. Transl Res 2012; 160:291-297.
7. Hurskainen Т., Moilanen J., Sormunen R. Transmembrane collagen XVII is a novel component of the glomerular filtration barrier. Cell Tissue Res 2012; 348: 579-588.
8. Miner J.H. The glomerular basement membrane. Exp Cell Res 2012; 318: 973-978.
9. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol 2011; 22: 1200-1207.
10. Bakun M., Niemczyk M., Domanski D. et al. Urine proteome of autosomal dominant polycystic kidney disease patients. Clin Proteomics 2012; 9: 13.
11. Rudnicki M., Perco P., Neuwirt H. et al. Increased renal ver-sican expression is associated with progression of chronic kidney disease. PLoS One 2012; 7: 9: http://www.ncbi.nlm.nih. gov/pubmed/23024773.
12. Webster N.L., Crowe S.M. Matrix metalloproteinases, their production by monocytes and macrophages, and their potential role in HlV-related diseases. J Leukocyte Biol 2006; 80: 1-15.
13. ПотеряеваО.Н. Матриксные металлопротеиназы: строение, регуляция, роль в развитии патологических состояний. Медицина и образование в Сибири 2010; 5: http:// ngmu.ru/cozo/mos/article/text_full.php?id=449 (Potery-aeva O.N. Matrix metalloproteinases: structure, regulation, role in the development of pathological conditions. Medicina i obrazovanie v Sibiri 2010; 5: http://ngmu.ru/cozo/mos/ar-ticle/text_full.php?id=449.)
14. Altemtam N., NahasM.E., Johnson T. Urinary matrix metallo-proteinase activity in diabetic kidney disease: a potential marker of disease progression. Nephron Extra 2012; 2: 219—232.
15. Бобкова КН., Козловская Л.В., Ли О.А. Матриксные металлопротеиназы в патогенезе острых и хронических заболеваний почек (Обзор литературы). Нефрология и диализ 2008; 10; 2: 105-111. (Bobkova I.N., Kozlovskya L.V., Lee О.A. Matrix metalloproteinases in the pathogenesis of acute and chronic kidney disease (review of literature). Ne-frologiyaidializ2008; 10; 2: 105-111.)
16. Бондарь И.А., Климентов В.В., Романов В.В. Мочевая экскреция матриксных металлопротеиназ и их ингибиторов у больных сахарным диабетом 1-го типа с нефропатией. Клин нефрол 2012; 5-6: 24-27. (BondarLA., KlimontovV.V., Romanov V.V. Urinary excretion of matrix metalloproteinases and their inhibitors in patients with type 1 diabetes with ne-phropathy. Klin nefrol 2012; 5-6: 24-27.)
17. Баширова З.Р, Длин В.В., Воздвиженская Е.С., Османов И. М Клиническое значение определения матриксных металлопротеиназ и их ингибиторов у детей с синдромом
18. Алыгорта. Клин нефрол 2014; 4: 51—57. (Bashirova Z.R., Dlin V.V. Vozdvizhenskaya E.S., Osmanov I.M. Clinical significance of determination of matrix metalloproteinases and their inhibitors in children with Alport syndrome. Kliniches-kaya nefrologiya 2014; 4: 51—57.)
19. Баширова З.Р., Воздвиженская E.C., Османов ИМ. Клиническое значение определения матриксных металлопро-теиназ и их ингибиторов у детей с аутосомно-доминант-ной поликистозной болезнью почек. Клин нефрол 2014; 2: 61—63. (Bashirova Z.R., fozdvizhenskaya E.S., Osmanov I.M. Clinical significance of determination of matrix metalloproteinases and their inhibitors in children with autosomal dominant polycystic kidney disease. Klinnefrol2014; 2: 61—63.)
20. Yanagita M. Inhibitors/antagonists of TGF-P system in kidney fibrosis. Nephrol Dial Transplant 2012; 10:27:3686-3691. "
21. Чеботарева Н.В., Бобкова И.Н., Козловская Л.В. и др. Определение экскреции с мочой моноцитарного хемо-таксического протеина-1 и трансформирующего фактора роста-Pj у больных хроническим гломерулонефритом как метод оценки процессов фиброгенеза в почке. Клин нефрол 2010; 3: 51-55. (Chebotareva N.V., Bobkova I.N., Kozlovskaya L.V. et al. Determination of urinary excretion of monocyte chemotactic protein-1 and transforming growth factor-Pj in patients with chronic glomerulonephritis as a method of evaluation of fibrogenesis in the kidney. Kliniches-kaya nefrologiya 2010; 3: 51-55.)
22. Дедова В.О., Доценко Н.Я., Боев С.С. и dp. Распространенность дисплазии соединительной ткани (Обзор литературы). Медицина и образование в Сибири 2011; 2: http://ngmu.ru/cozo/mos/article/text_full.php?id=478. (Dedova V.O., Dotsenko N.Ya., Boev S.S. et al. Prevalence of connective tissue dysplasia (review of literature). Medicina i obrazovanie v Sibiri 2011; 2: http://ngmu.ru/cozo/mos/ar-ticle/text_full.php?id=478)
23. Конюшевская А.А., Франчук М.А. Синдром недифференцированной дисплазии соединительной ткани. Пульмонологические аспекты. Здоровье ребенка 2012; 7: http:// www.mif-ua.com/archive/article/34950. (Konyushevska-уа А.А., Franchuk M.A. Syndrome of undifferentiated connective tissue dysplasia. Pulmonary aspects. Zdorov'e rebenka 2012; 7: http://www.mif-ua.com/archive/article/34950)
24. Nimisha K, Niranjan S.K. Ehler Danlos Syndrome: An Overview. J Chem Pharmac Res 2011; 3: 3: 98-107.
25. Шахназарова М.Д., Розинова Н.Н., Семячкина А.Н. Моногенные болезни соединительной ткани (синдромы Марфана и Элерса-Данло) и бронхолегочная патология. Земский врач 2010; 3: 17—22. (Shakhnazarova M.D., Rozinova N.N., Semyachkina A.N. Monogenic diseases of connective tissue (Marfan's syndrome and Ehlers Danlos) and bronchopulmonary diseases. Zemskiy vrach2010; 3: 17—22).
26. http://www.ehlersdanlos.org
27. TarrassF.,BenjellounM., Hachim К et al. Ehlers-Danlos syndrome coexisting with juvenile nephronophtisis. Nephrology (Carlton) 2006; 11: 2: 117-119.
28. Conway R., Bergin D., Coughlan R.J., Carey J.J. Renal infarction due to spontaneous renal artery dissection in Ehlers-Danlos syndrome type IV. J Rheumatol 2012; 39:1:199-200.
29. Клеменов А.В., Суслов А.С. Наследственные нарушения соединительной ткани: современный подход к классификации и диагностике (обзор). СТМ 2014; 6: 2: 128. (KlemenovA.V., SuslovA.S. Hereditary connective tissue dis-
30. orders: a modern approach to the classification and diagnosis (overview). STM 2014; 6: 2: 128.)
31. Chow K, Pyeritz R.E., Litt H.I. Abdominal vis-ceral findings in patients with Marfan syndrome. Genet Med 2007; 9: 4: 208-212.
32. Gupta A., Gaikwad J., KhairaA., Rana D.S. Marfan syndrome and focal segmental glomerulosclerosis: A novel association. Saudi J Kidney Dis Transpl 2010; 21: 754-755.
33. Udayakumar N., Sivapraksh S., Rajendiran C. A case of Marfan syndrome with aminoaciduria. J Postgrad Med 2007; 53: 214-215.
34. Cook, J.R., Ramirez F. Clinical, diagnostic and therapeutic aspects of the Marfan syndrome. Adv Exp Med Biol 2014; 802: 77-94.
35. Savige J., Gregory M., Gross O. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 2013; 24: 364—375.
36. Miner J.H., Baigent C, Einter F. et al. The 2014 International Workshop on Alport Syndrome. Kidney Int 2014; 86:4:679-684.
37. Beicht S., Strobl-Wildemann G., Rath S. et al. Next generation sequencing as a useful tool in the diagnostics of mosaicism in Alport syndrome. Gene 2013; 526: 474-477.
38. Потемкина А.П., Маргиева Т.В., Комарова О.В. и др. Возможности дифференциальной диагностики основных причин гломерулярной гематурии у детей. Клин нефрол 2012; 9: 3: 50-55. (Potemkina A.P., MargievaT.V., Komarova O.V. et al. The possibilities of differential diagnosis of the main causes of glomerular hematuria in children. Klin nefrol2012; 9: 3:50-55.)
39. Рахматуллина З.А. Соединительнотканные дисплазии у детей с хроничесими заболеваниями желудочно- кишечного тракта и органов мочевой системы. Автореф. дисс... канд.мед.наук. М., 2009; 25. (Rakhmatullina Z.A. Connective tissue dysplasia in children of chronic diseases of the gastrointestinal tract and urinary tract: Avtoref. diss.... k.m.n. Moscow, 2009; 25.)
40. Минаев СВ., Павленко И.В., Чумаков П.И. и др. Проявление дисплазии соединительной ткани у детей с врожденной патологией почек и мочевыводящей системы. Медицинский вестник Северного Кавказа 2014; 9: 3: 273-274. (Minaev S.V., Pavlenko I.V., Chumakov P.I. et al. The manifestation of connective tissue dysplasia in children with congenital disorders of the kidneys and urinary system. MedicinskiyvestnikSevernogoKavkaza2014; 9: 3: 273—274.)
41. Игнатова M.C., Морозов С.Л., Крыганова Т.А. и др. Современные представления о врожденных аномалиях органов мочевой в системы (синдром CAKUT) у детей. Клин нефрол 2013; 2: 58—64. (Ignatova M.S., Morozov S.L., Krygano-va Т.А. et al. Modern conceptions of congenital anomalies of the urinary congenital anomalies of the urinary system (syndrome CAKUT) in children. Klin nefrol 2013; 2: 58-64.)
42. Вялкова А.А., Зорин ИВ. Роль трансформирующего фактора роста р в формировании и прогрессировании интерстициального фиброза у детей с пузырно-моче-точниковым рефлюксом. Бюллетень Оренбургского научного центра УрОРАН (электронный журнал) 2013; 4: 1-10. http://www.elmag.uran.ru. (Vyalkova A.A. Zorin I.V. The role of transforming growth factor p in the formation and progression of interstitial fibrosis in children with puzyrno-ureteral reflux. Byulleten Orenburgskogo nauchnogo centra UrORAN 2013; 4: 1-10. http://www.elmag.uran.ru)
Review
For citations:
Kryganova T.A. Specific features of urinary system diseases in children with connective tissue dysplasia. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2015;60(6):33-37. (In Russ.)
Views:
1180
Email this article 